Notes
2018 US dollars
2018 Japanese yen
Reference
Kashiwa M, et al. Comparative Cost-Utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. Clinical Therapeutics : 9 Jul 2020. Available from: URL: http://doi.org/10.1016/j.clinthera.2020.05.014
Rights and permissions
About this article
Cite this article
Tipiracil/trifluridine cost effective for mCRC but not regorafenib. PharmacoEcon Outcomes News 858, 30 (2020). https://doi.org/10.1007/s40274-020-7003-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7003-2